Tag: Meeting

Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an investigational oral selective estrogen receptor degrader (SERD), vs. investigator's choice of endocrine monotherapy ...

- 92% (n=22/24) of Evaluable Patients Achieved Complete Response (CR) at the Initial 3-Month Timepoint from the Phase 2 Clinical Trial of CG0070, an Oncolytic Immunotherapy, in Combination with KEYTRUDA® ...

– Zandelisib Demonstrated 70.3% Objective Response Rate and 35.2% Complete Response Rate – – 87.5% of Responses Achieved in First Two Cycles of Therapy, 75% of CRs in First Four ...

Paris, June 2, 2022: HiPay (ISIN code FR0012821916 – ALHYP), the fintech specialized in Omnichannel payment solutions, announces the results of its Combined Shareholders’ Meeting of June 2, 2022.During the ...

SHANGHAI, China, June 02, 2022 (GLOBE NEWSWIRE) -- GDS Holdings Limited (“GDS Holdings,” “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China, today ...

NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail. NOTICE OF ANNUAL GENERAL MEETING IN ZETADISPLAY AB (PUBL) The ...

The shareholders of Anoto Group AB (publ) (the “Company”) are hereby invited to attend the Annual General Meeting (the “AGM”) to be held on Tuesday 28 June 2022 at 10 a.m. ...

NOIDA, India, May 30, 2022 /PRNewswire/ -- Curadev participated in the American Association for Cancer Research (AACR) 2022 annual meeting from April 8-13, 2022, in New Orleans, Louisiana. This year, ...

MONTREAL, May 27, 2022 (GLOBE NEWSWIRE) -- Nuvei Corporation (the “Corporation”) (Nasdaq: NVEI) (TSX: NVEI), tomorrow’s payment platform, today announced the results of its annual and special meeting of shareholders ...

ModraDoc006/r at 20-20/200-100mg dosage eliminated neutropenia and significantly decreased neuropathy while maintaining efficacy levels comparable to intravenous (IV) docetaxel Based on strong safety data and encouraging efficacy from the randomized ...